Mereo BioPharma Group

Mereo BioPharma Group ROA

The Return on Assets (ROA) of Mereo BioPharma Group (MREO) as of Nov 18, 2026 is -56.62 %. In the previous year, Return on Assets (ROA) was -44.31 % — a change of 27.78% (lower).

ROA

-56.62 %

YoY

27.78%

Last updated:

In 2024, Mereo BioPharma Group's return on assets (ROA) was -56.62 %, a 27.78% increase from the -44.31 % ROA in the previous year.

The Mereo BioPharma Group ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2017
-40.27 USD
Jan 1, 2018
-63.46 USD
Jan 1, 2019
-38.79 USD
Jan 1, 2020
-243.76 USD
Jan 1, 2021
10.60 USD
Jan 1, 2022
-39.54 USD
Jan 1, 2023
-44.31 USD
Jan 1, 2024
-56.62 USD
The Mereo BioPharma Group ROA history
YEARROAYoY
-56.62 %+27.78%
-44.31 %+12.07%
-39.54 %-473.00%
10.60 %-104.35%
-243.76 %+528.41%
-38.79 %-38.87%
-63.46 %+57.56%
-40.27 %+23.08%
-32.72 %+7.00%
-30.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mereo BioPharma Group Stock analysis

What does Mereo BioPharma Group do? Mereo BioPharma Group plc was founded in 2015 and is based in Reading, UK. The company is a pharmaceutical industry company that focuses on the development of treatments for rare and unmet medical needs. Mereo BioPharma is an emerging biotechnology company that discovers, develops, and markets innovative drugs. The company employs an experienced team of scientists and researchers dedicated to developing therapies that address unmet medical needs. Mereo BioPharma specializes in four areas of interest in which it is actively working on new developments: oncology, rare diseases, gynecological and endocrine disorders, and respiratory diseases. The company aims to advance innovative drug developments that focus on rare and unmet medical needs. These typically have received little attention from larger, established pharmaceutical companies. However, they represent a tremendous opportunity to identify and successfully bring to market high-quality and effective drugs. Mereo BioPharma is listed on the London Stock Exchange (AIM) and has a strong financial foundation. Mereo is preparing to launch two new products - Alvelestat and Setrusumab - for the treatment of respiratory diseases and osteogenesis imperfecta. Mereo's business model is based on a multi-stage development pipeline: from the discovery of potential drug candidates to clinical trials and marketing. The company works closely with established partners to pool the necessary resources and expertise required for the development and successful commercialization of an outstanding product. Alvelestat is a unique therapy specifically developed for patients with alpha-1 antitrypsin deficiency. The drug is used to treat lung and liver diseases often associated with this condition. It is currently in Phase II of clinical development. Setrusumab is an innovative product for the treatment of osteogenesis imperfecta, a rare bone disorder often diagnosed in early childhood. The drug is currently in Phase III of the approval process. The company's future plans include expanding its pipeline to create treatment options for patients worldwide. Mereo utilizes advanced technologies and modern methods to foster research, development, and clinical studies and ensure the success of its products in the market. Mereo BioPharma Group plc is a young, exciting company specializing in the development of drugs for the treatment of rare and unmet medical needs. The company focuses on three strategic priorities: research and development of innovative drugs, collaboration with strong partners, and marketing and distribution of its products. Mereo has a strong financial foundation and is committed to expanding its pipeline to meet new patient needs. Mereo BioPharma Group is one of the most popular companies on Eulerpool.

ROA Details

Understanding Mereo BioPharma Group's Return on Assets (ROA)

Mereo BioPharma Group's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Mereo BioPharma Group's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Mereo BioPharma Group's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Mereo BioPharma Group’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Mereo BioPharma Group stock

Return on Assets (ROA) of Mereo BioPharma Group is -56.62 % in 2024.

Return on Assets (ROA) of Mereo BioPharma Group changed from -44.31 % to -56.62 %, representing a 27.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Mereo BioPharma Group since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Mereo BioPharma Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Mereo BioPharma Group

All Key Metrics — Mereo BioPharma Group